Street Talk: Patent Issues Could Dominate Pharma Industry in 2006 - Proposed reforms on current patent practices could hand pharma substantial losses of revenue and diminished profit margins -

ADVERTISEMENT

Street Talk: Patent Issues Could Dominate Pharma Industry in 2006
Proposed reforms on current patent practices could hand pharma substantial losses of revenue and diminished profit margins


BioPharm International
Volume 19, Issue 1

But Congress is also looking at ways to curb longer patent protection time periods. Right now, biopharmaceutical firms enjoy roughly 20 years of drug patent protection for their brand-name drugs. The Hatch-Waxman Act would limit the automatic extensions filed by drug makers.

So is it too soon to call 2006 the Year of the Patent? Maybe, or maybe not.

But one thing is for sure. For a heads-up on long-term profit margins for big biopharmaceutical companies and the generic drug companies chasing them, patent reform is well worth watching closely.

Celebrity author and business/finance commentator for CNN and Fox News, Brian O'Connell has written for The Wall Street Journal and Newsweek, 79 Radcliffe Drive, Doylestown, PA 18901, 215.230.3711, fax 267.880.1939,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here